Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. The company has no approved products and generates no revenue. Its primary activities involve the development of two lead product candidates: rinzimetostat (PRC2 inhibitor for prostate cancer) and enozertinib (EGFR inhibitor for non-small cell lung cancer). In August 2025, the company executed a strategic pipeline prioritization, eliminating its discovery research group and reducing its workforce by approximately 20% to focus resources on these two programs.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(77,259) | $(66,376) | $(41,492) |
| Loss Per Share (Basic & Diluted) | $(0.72) | $(0.89) | $(0.38) |
| Operating Expenses | $84,915 | $71,782 | $45,296 |
| Research & Development (R&D) | $67,733 | $55,189 | $36,296 |
| General & Administrative (G&A) | $17,182 | $16,593 | $9,000 |
| Cash, Cash Equivalents & Investments | $387,560 | $392,250 (Dec 31, 2025) | N/A |
| Net Cash Used in Operating Activities | $(64,043) | $(63,375) | N/A |
| Net Cash Provided by Financing Activities | $61,968 | $134,313 | N/A |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss for the six months ended June 30, 2026, increased by $10.9 million compared to the same period in 2025, driven primarily by higher R&D expenses.
- R&D Expense Growth: R&D expenses increased by $12.5 million year-over-year. This was driven by increased external costs for the advancement of rinzimetostat (up $16.0 million), partially offset by lower costs for enozertinib due to timing of manufacturing and clinical costs.
- Financing Activity: Net cash provided by financing activities decreased significantly to $62.0 million from $134.3 million in the prior year. This reflects the absence of the large private placement that occurred in May 2025. During the current six-month period, the company raised approximately $59.9 million via At-The-Market (ATM) offerings.
- Investment Portfolio: Total cash, cash equivalents, and investments decreased slightly to $387.6 million from $392.3 million at year-end 2025, reflecting operating cash burn offset by financing proceeds.
Guidance, Outlook, and Risks
- Clinical Progress:
- Rinzimetostat: In July 2026, the company initiated its first global Phase 3 registrational trial (Himalayas-1) in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). A collaboration with Bayer provides darolutamide at no cost for this trial.
- Enozertinib: The company expects to report data in the second half of 2026 for first-line NSCLC patients with EGFR exon 20 insertion mutations.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($387.6 million) are sufficient to fund operations into the second half of 2028. No specific revenue guidance is provided as the company has no commercial products.
- Key Risks:
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.
- Regulatory Uncertainty: Risks include the potential for clinical trial failure, delays in regulatory approval, and changes in FDA policies (e.g., Project Optimus).
- Third-Party Dependence: Reliance on third-party manufacturers for API and drug product, and third-party CROs for clinical trials.
- Legal/Compliance: The Chief Business Officer is currently appealing an SEC civil enforcement action regarding insider trading unrelated to Oric. Additionally, the company faces risks related to trade tariffs and the BIOSECURE Act regarding Chinese suppliers.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $387.6 million cash position against the projected burn rate to confirm the "second half of 2028" funding timeline.
- Phase 3 Trial Initiation: Confirm the enrollment status and timeline for the Himalayas-1 Phase 3 trial for rinzimetostat initiated in July 2026.
- Cost Structure: Monitor the impact of the August 2025 workforce reduction (20% cut) on future operating expenses and whether anticipated cost savings are being realized.
- Financing Needs: Assess the likelihood and terms of future equity or debt financing required to bridge the gap between current cash and commercialization.
- Supply Chain: Evaluate exposure to geopolitical risks and tariffs regarding third-party manufacturers, particularly those in China, as highlighted in the risk factors.